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Endocrinological late effects after chemotherapy for testicular cancer
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Summary Type and extent of endocrinological alterations were studied in long-term disease-free survivors
after cisplatin-based chemotherapy for testicular cancer. A total of 63 patients with a median age of 30 (19-53)
years, and median follow-up of 42 (16-128) months were included. Elevated serum follicle-stimulating
hormone (FSH) levels were found in 63% ofpatients, 24% showed pathologically elevated luteinising hormone
(LH) levels with normal and 10% with subnormal testosterone levels. The degree of gonadotropin elevation
was highly significantly correlated with the cumulative platinum (P) dose. Patients treated with platinum-
vinblastine-bleomycin regimens showed higher gonadotropin levels than those treated with platinum-
etoposide-bleomycin. The adrenal androgen dehydroepiandrosterone (DHEA), pathologically elevated in 68%
of patients, was significantly correlated with the cumulative doses of chemotherapy (ctx) used and to the
gonadotropin levels. Treatment variables, such as type and dose of cytotoxic agents used, as well as degree of
gonadotropin elevation were further correlated with changes in oestron, testosterone and 17a-OH-progesterone
levels. Cholesterol levels were elevated in 32% of patients and significant interactions between the steroid
hormone levels and cardiovascular risk factors could be shown.
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Alterations in the hormonal equilibrium seem to persist in
more than 50% of young men treated for testicular cancer,
disrupting the physiological age- and gender-specific home-
ostasis of steroid hormones, with potential influence on the
development of cardiovascular risk factors.
The introduction of effective chemotherapy (ctx) for
patients with metastatic testicular cancer has resulted in a
tremendous number of young patients being cured of their
malignant disease. Today approximately 80% of patients can
be rendered long-term disease free by 3-4 cycles of a
combination therapy with cisplatin (P), etoposide (E) and
bleomycin (B), followed by secondary surgery. With the
success of cytotoxic treatment, possible long-term side-effects
have come to be of concern for these young patients who can
expect to live for another 30-50 years after treatment of
their tumour.
In recent years several studies have been conducted
concerning later toxicities after ctx for testicular cancer such
as neurotoxicity, ototoxicity, vascular toxicity, renal damage
and infertility (Aass et al., 1990; Bissett et al., 1990; Roth et
al., 1988; Schwabe et al., 1992), but few data have been
available on endocrinological changes, although there is
evidence of multiple ctx-related endocrine abnormalities
(Bokemeyer et al., 1994; Giona et al., 1994). The
implications of ctx-induced gonadal toxicity go beyond the
occurrence of infertility, since subtle shifts in hormonal ratios
might influence the physiological equilibrium necessary for
maintaining health and well being. Alterations of gonadal
hormones and their regulatory proteins may influence
multiple body functions, such as bone and mineral home-
ostasis (Holmes et al., 1994), steroid metabolism and lipid
profiles (Barrett-Connor and Khaw, 1988).
Information available on serum cholesterol levels after ctx
is limited and partially controversial (Ellis et al., 1992;
Gietema et al., 1992; Raghavan et al., 1992) and little is
known on the potential associations between cholesterol
levels and changes of sex hormones or adrenal androgens -
hormones that themselves have been postulated to be related
to life expectancy and ageing (Barrett-Connor et al., 1986).
The interactions between these hormones and cholesterol
metabolism may influence the risk of cardiovascular disease.
Cases of myocardial infarctions have been observed in the
young cohort of patients treated for testicular cancer (Berger
et al., 1995; Roth et al., 1988).
It is the aim of the current study to investigate the type,
extent and reversibility of endocrinological alterations in
long-term survivors of testicular cancer treated with cisplatin-
based combination ctx. In addition, the influence of
individual patient characteristics on the occurrence of late
endocrinological toxicity is investigated.
Material and methods
Patients
A total of 66 of 182 patients treated for testicular cancer at
Hannover University Medical School between 1976 and 1987
agreed to take part in a study concerning the detection of
possible endocrinological late toxicities following ctx. All
patients had been in complete remission for at least 12
months after ctx. Three patients were omitted from this
study, two with bilateral orchidectomy and exogenous
gonadal hormone substitution and one intersexual patient
with primary gonadal dysfunction. The characteristics of the
remaining 63 patients included in this study are given in
Table I. The data on tumour stage, laboratory values before
and during ctx, and treatment variables - including the
regimens used, cumulative drug dosages and additional
medication - were extracted from the patients' charts. A
personal medical history, including current complaints,
regular use of medication and smoking status was obtained
by interview on the day of the blood test for endocrinological
assessment. All 63 patients were without acute illnesses and
none were taking medications known to influence the
pituitary-testicular axis, other endocrine functions or lipid
metabolism.
Laboratory analyses
After a rest period of at least 15 min a blood specimen was
obtained from each patient by puncture of an antecubital
vein in a sitting position. In order to gain comparable
interindividual values of circadian fluctuating sexual hor-
mones all blood samples were collected between 12.00 and
13.00 h. As overnight fasting was not feasible owing to the
ambulatory setting, the patients had been advised to have a
light breakfast around 08.00 h, based on existing recommen-
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November 1995dations that measurement of non-fasting total cholesterol
concentration is sufficient for the screening of cardiovascular
risk factors (Neil et al., 1990). All blood samples were
analysed according to the established standards at Hannover
University Medical School. y-Glutamyltransferase, alanine
and aspartate transaminases were determined for screening
for liver function, plasma electrophoresis was performed for
the calculation of the absolute albumin fractions and plasma
creatinine, electrolytes and lactate dehydrogenase as well as a
full blood count were performed to rule out major disorders.
Total serum cholesterol was measured enzymatically by an
automated procedure with standard enzyme kits. The
following commercially available kits were used for the
quantitative determination of hormones: FSH MAlAclone
(Seronodiagnostics, Biodata, Italy; immunoradiometric assay
(IRMA) for follicle-stimulating hormone), LH-CTK irma
(Sorin, Biomedica, Italy; IRMA for luteinising hormone),
[3H]Oesterone-, [3H]17a-hydroxyprogesterone- and [3H]S-
DHA-RIA-Kit, ['25J]Oestradiol-COATRIA [bioMerieux,
France; radioimmunoassays (RIAs) for oestrone, 17a-
hydroxyprogesterone, dehydroepiandrosterone sulphate and
oestradiol], DHEA Test Set (Wiven Laboratories, NJ, USA;
RIA for dehydroepiandrosterone), Estronosticon Elisa
System (Organon Teknika, Belgium, enzymeimmunoassay
for total oestrogens, reacting to the same extent with
oestrone, oestradiol, oestriol and oestrogens conjugated at
sites 16 and 17), Testosterone Antiserum (Farmos Diagnos-
tica, Finland) with NET-187 Testosterone [lf,2#-3H(N)] as
tracer (New England Nuclear, MA, USA; RIA after
testosterone extraction with diethylether). None of the
patients had elevated fl-hCG levels at the time of elevation,
which might have interfered methodologically with the
determination of LH levels and which may have physiologi-
cally influenced oestrogen and FSH metabolism (Cochran et
al., 1975).
Statistical analyses
Statistical analyses were performed using SPSS for Windows
6.0 software. Association between hormone serum levels and
variables of interest were estimated using Pearson's product-
moment correlation coefficients and Spearman's rank-sum
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test when indicated. Partial correlation coefficients were
computed after adjustments for age or other potential
factors of influence in particular cascs. Diffcrcnces bctwecen
means were analysed using Student's t test, Mann-Whitney
U rank-sum test and Kruskal-Wallis H-test as appropriate.
The chi-square test was applied to categorical variables. The
tests were two-tailed and significance was accepted at the
P 0.05 level.
Results
Endocrine profiles were altered in 40 (63%) of 63 patients
after ctx for testicular cancer. Disturbances were found
especially in the pituitary-testicular axis with elevations of
FSH and LH in 63% and 35% of patients respectively and
for the adrenal androgen dehydroepiandrosterone (DHEA)
with elevations in 68% and for 17aOH-progesterone (17-OH-
pr) in 51% of the patients. Median values, range and
laboratory normal values of these hormones as well as for
testosterone (T), oestradiol (E2), oesterone (El), total
oestrogens (tEs), dehydroepiandosterone sulphate (DHEAS)
and total cholesterol (Chol) serum concentrations are shown
in Table II.
Testosterone and gonadotropins
Five different types of gonadal hormone profiles were
distinguished in our patients: (1) 18 (29%) patients with
normal FSH, LH and T levels i.e. intact gonadal function; (2)
18 (29%) patients with elevated FSH only (range: FSH 16-
27.7 yIU ml-'), indicating a disturbance of seminiferous
tubule function; (3) 15 (24%) patients with LH and FSH
elevation (range: LH 15-53 ,IU ml-', FSH 20-64.9 AIU
ml-1) and normal T levels, implying compensated Leydig cell
insufficiency and impaired spermatogenesis; (4) six (10%)
patients with LH and FSH elevation and low T (range: LH
18.1-30.2 yIU ml-', FSH 30.9-49.3 jlU ml-', T 1.5-3.0
ng ml-'), indicating impaired spermatogenesis and decom-
pensated Leydig cell insufficiency; and (5) four (6%) patients
with low T only (range: T 2.4-2.9 ng ml-1). For two (3%)
patients hormone profiles could not be interpreted.
Table I Characteristics of 63 patients treated with cisplatin-based combination chemotherapy for testicular cancer who were evaluated for late
endocrinological toxicity
Number ofpatients
Primary tumour
Gonadal
Extragonadal
Stage (Lugano classification):
-I
-II
-III
Treatment
Chemotherapy:
PVB
Standard-dose PEB
High-dose PEB
PEB +Vcr
PEB+V or PBV+PE
Other
Radiotherapy (abdominal)
Orchidectomy (unilateral)
Patient characteristics
Smoker
Non-smoker
Former smoker/occasional smoker
Overweight according to Broca-index
Age at time of study (years)
Age at time of ctx (years)
Duration of complete remission (months)
60
3
5
21
37
21
12
10
7
6
7
6
60
28
27
8
20
30
26
42
(%)
(95)
(5)
(8)
(33)
(59)
(33)
(19)
(15)
(11)
(10)
(11)
(10)
(95)
(45)
(43)
(12)
(32)
Range
19-53
17-50
16- 128
P, cisplatin; E, etoposide; B, bleomycin; V, vinblastine; Vcr, vincristine; ctx, chemotherapy.Endocrinological sequelae after chemotherapy
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Elevation of LH and FSH levels were positively correlated
[correlation coefficient (CC) 0.76; P<0.001]. The degree of
serum hormone level alteration varied according to different
cytotoxic agents and doses (see Figure 1 for details). The
cumulative cisplatin dose proved to be a significant risk
factor for FSH (P=0.006) and LH (P=0.01) elevations in all
patients and among protocol-stratified subgroups. Compar-
able cisplatin- and bleomycin-based regimens containing
etoposide (PEB) instead of vinblastine (PVB) seemed to
result in less gonadal toxicity [LH elevations in 8% vs 33% of
patients respectively (NS) and FSH elevation in 50% vs 75%
of patients respectively. (P<0.05)]. Patients who had received
both etoposide and vinca alkaloids were at a significantly
higher risk for FSH elevations than patients receiving only
one of these agents.
Owing to adjustments for a possible bias caused by factors
such as differing times of follow-up after different ctx
regimens (PEB and PVB) affecting patient age, or the use
of higher cumulative cisplatin doses in advanced disease
patients, it was necessary to also compare smaller subsets of
patients. Patients >28 years at the time of ctx showed a
tendency towards higher FSH (Figure 2), LH and lower T
levels in most subgroups. A statistically significant decrease
of gonadotropin levels with time since ctx application was
found only for FSH in patients who had received regimens
with high gonadal toxicity (cumulative cisplatin dose >400
mg m-2) (P=0.02). Although as a trend the gonadotropins in
this patient group decreased with time, levels still remained
elevated compared with normal values despite a median of 57
months of follow-up.
The mean T levels were significantly (P=0.017) influenced
by the cumulative cisplatin doses applied (lower T levels in
patients with >400 mg m-2 cisplatin compared with patients
with .400 mg m-2 cisplatin). Application of steroids for
antiemesis during ctx, smoking status, liver function and
serum albumin concentration did not significantly influence
gonadotropin or T levels.
Adrenal androgens
Serum DHEA levels were studied in 28 patients. A total of 19
(68%) patients presented values elevated above the labora-
tory normal value. Although a physiological age-dependent
decline has been described (Zumoff et al., 1980) only a minor
trend for lower DHEA levels in older patients was noticed
although the negative correlation between DHEA and age
increased when being controlled for toxicity parameters, such
as the cisplatin dose or gonadotropin levels. DHEA levels
were significantly correlated to the cumulative dose of
cisplatin (CC 0.51; P=0.006). Accordingly, DHEA levels
were correlated with LH and FSH levels (CC 0.64; P< 0.001
and 0.55; P=0.003). Similar associations were seen between
DHEA and the cumulative doses of etoposide (CC 0.51) and
vinblastine (CC 0.66).
A total of 34 patients were studied for serum DHEAS
levels. The physiological decrease in DHEAS with age was
seen in our patient group with a significant CC of -0.34.
The negative correlation of age and DHEAS increased
(CC-0.58) in patients receiving high cumulative cisplatin
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Figure 1 Median serum gonadotropin levels and their ranges
after cisplatin-based chemotherapy for testicular cancer with
respect to the type of chemotherapy treatment regimens (boxes
represent 25th-75th percentiles excluding extremes). P, cisplatin;
V, vinblastine; E, etoposide; B, bleomycin; vincas, vinca alkaloids;
hd, high dose; sd, standard dose; FSH, follicle-stimulating
hormone; LH, luteinising hormone. The dashed lines represent
the upper limit of normal LH (---) and FSH --- - -) levels. ,
FSH; , LSH.
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Figure 2 Median serum follicle-stimulating hormone (FSH)
concentrations and ranges (brackets) in relation to age at time
ofchemotherapy (ctx) [l, <28 years; *, >28 years; size of boxes
represents 25th-75th percentiles). P, cisplatin; V, vinblastine; E,
etoposide; B, bleomycin; vincas, vinca alkaloids; sd, standard dose
cisplatin; hd, high dose cisplatin.
Table II Median serum hormone and cholesterol levels at the time of evaluation for endocrinological late toxicity after cisplatin-based
combination chemotherapy for testicular cancer
Median values Percentage ofpatients
Normal values (range) with elevated values
Follicle-stimulating hormone (,IU ml-1) < 12 19.8 (4.9-64) 63%
Luteinising hormone (,uIU ml-) <15 11.4 (2.4-53) 35%
Testosterone (ng mg 1) <3 5.0 (1.5-11.1) 17%a
DHEAS (ng ml-1) <5000 3267 (657-6010) 11%
DHEA (ng ml-') <5 5.5 (1.7-18.5) 68%
Oestradiol (E2) (pg ml-') <80 49 (9.1-93.2) 8%
Oestrone (El) (pg ml-') <80 50 (11.8-100.3) 13%
Total oestrogens (nmol mlr) <6 5.4 (2.3-7.9) 33%
17a-OH-progesterone (ng dl-') < 125 127 (28.4-389.1) 51%
Total cholesterol (mmol 1') <6.7 5.9 (3-8.6) 32%
Normal values are based on standard serum concentrations in a healthy male population. DHEAS, dehydroepiandrosterone sulphate; DHEA,
dehydroepiandrosterone. aDecreased value.
I-- - ---- I II~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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doses and in patients older than 35 years (CC -0.8). The
mean/median values showed an age peak at 30-35 years
instead of 20-25 years as would be considered normal in a
healthy male population (Orentreich et al., 1984). The
following decline with age was more pronounced than
normally found in men of 40-50 years. The association of
serum DHEAS levels with ctx-related toxicity was not as
distinct as for DHEA; however, the four (12%) patients with
pathologically low levels of DHEAS despite age adjustment,
all showed extremely high gonadal hormone toxicity profiles
(mean FSH 39.3 ,uIU ml-') compared with the average values
of all 34 patients (FSH 22.1 ,uU ml-').
No other factors of influence - apart from the cumulative
doses of cytotoxic agents and age dependency - on adrenal
androgen levels were identified.
Other testicular and adrenal steroids
Compared with normal laboratory range values for men,
serum 17-OH-pr was elevated in 32 (51%) and tE in 21
(33%) of the 63 patients studied (see Table II). El and E2
levels were elevated in only eight (13%) and five (8%) of
patients. As there was a strong negative correlation between
liver function parameters and these steroids, e.g. liver enzyme
elevations and El in <30 year-old patients: CC -65;
P=0.002, three patients with alcohol-related major liver
dysfunctions were excluded from further evaluation. Unless
stated otherwise, the statistical analyses included the
remaining 60 patients and the 47 patients with completely
normal liver function parameters separately. Minimal
elevations of liver parameters were not found to be related
to any of the cytotoxic agents or their doses applied during
previous ctx and serum albumin concentrations were not
found to influence the following calculations.
Positive correlations were established between El levels
and DHEA (CC 0.47; P=0.012), and to a lesser degree
between El and LH levels (CC 0.27; P=0.035). E2 and T
levels were significantly correlated (CC 0.35) as would be
expected owing to the shared metabolical pathway. tE levels
were only correlated with El at a level of statistical
significance (CC 0.30; P =0.019). The statistically highly
significant correlation of 17-OH-pr with T (CC 0.46;
P<0.001) was confirmed in all subgroups and accordingly,
17-OH-pr and LH correlated well (CC 0.4; P =0.002).
Furthermore, correlation of 17-OH-pr with DHEA reached
statistical significance (CC 0.37; P=0.05).
Patient age was positively correlated with E2 (P=0.018)
and negatively to El levels (P=0.008). The strongest
correlation between E2 and tE or T, as well as between 17-
OH-pr and T was found in patients < 28 years of age.
El levels seemed to be influenced by the application of
vincristine during ctx, with mean El levels of 50.1 pg ml- 'in
51 patients without and of 71 pg ml-' in nine patients with
vincristine (CC 0.67; P=0.001). A trend towards increased
levels of tE and E2 with higher cumulative doses ofetoposide
applied was observed (NS).
Serum cholesterol and body mass index
Total serum cholesterol (Chol) concentrations were measured
in all 63 patients and elevation > 6.7 mmol I' occurred in 20
(32%) patients. The body mass index (BMI) - calculated as
weight (kg) divided by height squared (m2) - was used as an
index for obesity. Based on a cut-off value >25 for BMI,
(according to the Broca index), 20 (32%) patients were
considered as being overweight.
A highly significant correlation was established for patient
age with Chol (CC 0.39) and BMI (CC 0.42). Furthermore,
Chol and BMI correlated with each other (CC 0.5; P=0.001;
age-adjusted CC 0.34; P=0.03). Since both Chol and BMI
were significantly correlated with elevated liver function
parameters (CC 0.5; P=0.001) the following analyses were
carried out for patients with normal liver functions
separately.
Adrenal androgens were correlated with Chol levels and
BMI: DHEAS with Chol adjusted for age (CC 0.51;
P=0.005) and with BMI in patients <40 years (CC 0.6;
P=0.02). Age-stratified correlation coefficients for DHEA
with BMI and and with Chol in patients <40 years were 0.74
(P=0.009) and 0.53 (P=0.008) respectively.
Sex gonadal hormones correlated with possible cardiovas-
cular risk factors only in patients >30 years of age: E2 with
BMI (CC -0.4; NS), El with Chol (CC 0.48; P=0.03) and
with BMI (CC -0.51; NS); T correlated negatively with both
BMI and Chol (CC s-0.49 and -0.47 respectively; NS), and
17-OH-pr with Chol (CC -0.47; P =0.044).
A trend towards a correlation between treatment
modalities and cardiovascular risk factors such as BMI and
Chol levels was observed. The cumulative dose of cisplatin
and Chol level elevations were significantly correlated only in
patients <28 years (P=0.05).
Discussion
In 1948 Spitz was the first to describe testicular atrophy in
patients treated with nitrogen mustard for lymphoma.
Consecutive studies in patients with lymphoma have
particularly investigated the degree of exocrine gonadal
damage due to ctx (Bokemeyer et al., 1984). In the last
decade long-term toxicity has also become relevant to
patients with testicular cancer, as the use of combination
ctx and the introduction of cisplatin (Einhorn and Donohue,
1977) have resulted in potentially curative treatment. Yet,
data on endocrine toxicity in patients with testicular
tumours have mainly focused on fertility issues, and only
a few investigations were concerned with additional long-
term endocrinological abnormalities of hormone metabolism.
Besides sporadically documented minor thyroid-stimulating
hormone elevations (Bosl and Bajorunas, 1987; Gietema et
al., 1992; Leitner et al., 1986; Schwabe et al., 1992),
alterations in oestradiol levels have been found in patients
treated for testicular cancer (Gietema et al., 1992; Schwabe
et al., 1992), but the impact of these findings, e.g. on lipid
profiles and further metabolic changes, were not investi-
gated.
Although patients with testicular cancer may have an
increased incidence of pre-existing gonadal disorders (Carroll
et al., 1987), it is generally accepted that ctx can significantly
alter the gonadal function (Bosl and Bajorunas, 1987). Other
factors influencing the regulation of the pituitary-testicular
hormone axis may be the malignancy itself, which can
adversely affect gonadal function (Blackman et al., 1988) and
the secretion of,B-hCG by the tumour, which may influence
gonadotropin levels (Cochran et al., 1975). However, these
tumour-associated factors can be disregarded in long-term
surviving patients after ctx. An influence of unilateral
orchidectomy on sex hormone steroid levels has been denied
(Hoeppner et al., 1986). Therefore, the present study
investigates persisting abnormalities in the male steroid
hormone equilibrium following different combination ctx
protocols for testicular cancer, in order to identify possible
endocrinological damage resulting from ctx. Besides the
impact of ctx itself, additional variables such as age, time
of follow-up, liver metabolism, serum albumin concentration
were taken into consideration and all calculations were
performed for the total patient population and for
appropriately stratified subgroups.
To evaluate testicular function, serum testosterone (T),
and the gonadotropins secreted by the pituitary gland, FSH
and LH have to be determined (Horton, 1990). Elevated
serum FSH concentrations, probably resulting from deficient
secretion of inhibin and sex steroids (Horton, 1990), serve as
a reliable marker for tubular dysfunction and infertility, as
investigations of spermatogenesis after ctx have shown (Fossa
et al., 1985; Kreuser et al., 1989). LH levels rise when
testosterone production in the testicular Leydig cells falls.
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Testosterone is either maintained at a physiological level-
the compensated state - or decreases despite elevated LH
levels, resulting in hypogonadism.
Despite the pulsatile excretion mode of LH from the
pituitary gland, single LH values taken at a set time of day
were highly correlated with FSH levels (CC 0.76; P<0.001),
indicating the usefulness of single determinations of
gonadotropins at a fixed time (Bain et al., 1988) and their
value as reliable parameters of gonadal damage.
Controversial data have been reported on the issue of
return of fertility with time after ctx (Bissett et al., 1990;
Drasga et al., 1983; Hansen et al., 1990; Kreuser et al., 1989).
Our results of 63% elevated FSH levels at a median time of
42 months after ctx (1-11 years) and the degree of FSH
elevation, which correlates highly significantly with the
cumulative dose of cisplatin administered, imply that the
damage to spermatogenesis persists in the majority of
patients. Only two of ten patients with elevated FSH levels
who were also studied before ctx had previously shown
elevated FSH values. The occurrence of gonadal toxicity
correlated significantly with cisplatin-induced neuro- and
ototoxicity in our patients, confirming the impact of
cisplatin-based ctx on gonadal impairment (Berger et al.,
1995; Bokemeyer et al., 1993).
Furthermore, a correlation between cisplatin dose and LH
levels was documented. Although normalisation of elevated
LH levels with the time of follow-up has been suggested
(Leitner et al., 1986), a relevant decrease in LH and FSH
level elevation was seen only in the subset of our patients
who had received rather toxic high-dose platinum-based
regimens resulting in initially very high gonadotropin levels.
In all other treatment groups long-term median LH and FSH
elevations persisted or even slightly increased as compared
with levels of patients with short observation periods. Thus,
our findings do not help enlighten this controversial issue.
A total of 24% of our patients showed endocrinological
profiles of a compensated, and 10% of patients of a
decompensated, Leydig cell insufficiency. Regarding the
median age of 31 years of these patients and the average
follow-up of 37 months, impaired Leydig cell function in one-
third of all treated patients represents a considerable long-
term toxicity. Although the testosterone levels did not
decrease any further with the time of follow-up, it is too
early to conclude that the compensated Leydig cell
insufficiency will return to normal or at least remain stable
with time in all patients. Since the median testosterone levels
were lower after more toxic regimens - in addition to the
physiological decrease in testosterone with age - the
increased risk of ctx-treated patients for developing
premature Leydig cell insufficiency should be kept in mind.
Most data concerning ctx-related gonadal toxicity for
testicular cancer are based on PVB ctx (Einhorn and
Donohue, 1977). Although a similar degree of gonadal
toxicity has been postulated for vinblastine (V) and etopo-
side (E) used as single agents (Hansen et al., 1990), the
current standard regimen for PEB (replacing V by E) was
shown to be significantly less gonadotoxic in our patients
compared with PVB therapy, when similar cumulative doses
of P and B were given. The highest levels of gonadotropins
were reached in patients treated with regimens containing
both E and V or high-dose P.
It has been postulated that male patients over 25 years of
age treated with ctx may be more susceptible to persisting
gonadal impairment than younger patients (Horwich et al.,
1995; Leitner et al., 1986). A toxicity-age correlation could
be seen for FSH levels in our patients and statistically
significant differences of LH and FSH elevations were found
in patients <28 vs ) 28 years after treatment when low-
toxicity regimens were considered. As this result is not
consistent for all patient groups and as the physiological
increase of gonadotropins with age may represent a bias for
interpretation (Blackman et al., 1988), this issue will need
further investigation.
As corticosteroids cause oligospermia and low sperm
motility (Mancini et al., 1966), we analysed gonadal toxicity
with respect to the use ofhigh-dose antiemetic steroids during
therapy. No influence of steroids could be established. In a
study by Hendry et al. in 1983 patients with severely
depressed sperm counts before ctx had shown a greater
potential for recovery after ctx than those with normal
counts. However, pharmacological gonadal protection with
LH-releasing hormone analogues applied during ctx has so
far failed to achieve the protection promised by earlier
experimental studies (Krause and Pflueger, 1989). Accord-
ingly, in our patients, suppressed FSH levels, as noted in 3 of
14 patients screened before ctx, did not protect against
gonadal toxicity.
17a-OH-progesterone constitutes quantitatively the second
steroid secreted from the testis (Horton, 1990). Its function in
man is not known - it does not seem to be a sex steroid or a
regulator of gonadotropins. Therefore, our observation that
17a-OH-progesterone levels correlated with LH and testos-
terone, and increased significantly with the extent of tubular
damage remains without clinical interpretation.
DHEAS, a 15-androgen, is the major secretory steroidal
product of the adrenal gland. Together with its unconjun-
gated form, DHEA, these adrenal androgens had tradition-
ally been considered to be solely prohormones of stronger sex
steroids. Recently, it has become clear that, by means of
steroid sulphotransferase/sulphate interconvertable hor-
mones, they themselves participate in a striking number of
physiological and pathological processes (Parker, 1995),
although gross symptoms of clinical withdrawal following
experimental adrenalectomy are not observed (Regelson et
al., 1994). The metabolism of DHEAS with its unique
physiological age-dependent decline after a peak at the age of
approx 24 years (Orentreich et al., 1984) has been considered
as a marker for life expectancy and biological ageing
(Barrett-Connor et al., 1986). Despite a circadian rhythm,
single-spot samples measured at a standardised time of day
can give representative information on DHEAS levels (Bain
et al., 1988).
In our patients DHEAS levels were negatively correlated
with age as expected, but DHEA levels failed to show this
age-dependent fluctuation. However, DHEA levels correlated
highly significantly to the cumulative P dose applied, as well
as to LH and FSH levels. Furthermore, an influence of the
cumulative doses of E and V was established, postulating an
effect of combination ctx on DHEA metabolism, thus
altering normal age ranges. Despite the high variability in
DHEA level measurements (Zumoff et al., 1980), correlation
coefficients from 0.51 to 0.66 with levels of statistical
significance from P<0.001 to <0.006 for DHEA levels and
toxicity parameters in our patients indicate more than
coincidental hormone distributions.
Since DHEA/DHEAS ratios are not constant interindivi-
dual variables, but rather dependent on numerous known -
e.g. the extremely interindividual variable activity of the
converting enzyme steroid sulphotransferase (Aksoy et al.,
1993) - and unknown factors (Liu et al., 1990; Zumoffet al.,
1980), the influence and mechanisms of 'treatment toxicity'
on DHEA/S levels are difficult to interpret. LeBlanc et al.
(1992) and Maines et al. (1990) have shown that cisplatin has
an impact on steroidogenic pathways by influencing the
regulation of the cytochrome system as well as altering the
testicular mitochondrial sidechain cleavage activity. Yet, the
exact sites and definite mechanisms of metabolic dysregula-
tion, especially in long-term toxicity, have not been
determined and especially the clinical significance of possible
interference with the physiological age-distribution of the
adrenal androgens will remain to be investigated.
Oestrogens and androgens may play an important role in
the development ofrisk factors for cardiovascular disease and
the association of these steroid hormones with lipid profiles
(Haffner et al., 1993), degree of obesity and fat distribution
(Pasquali et al., 1991) appears to be established. Oestrogens
are associated with increased levels of high-density lipopro-
tein (HDL) cholesterol, which may decrease the cardiovas-F-d - ar -
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cular risk (Jacobs et al., 1990). Recently, two publications
have evaluated the treatment-related cardiovascular risk
profile in patients with testicular cancer (Gietema et al.,
1992; Raghavan et al., 1992). Gietema et al. demonstrated
that cholesterol levels and body fat increased significantly in
patients <29 years after ctx compared with patients treated
with orchidectomy alone. Elevated cholesterol levels have
also been mentioned in studies of long-term toxicity after ctx
for testicular cancer (Boyer et al., 1990; Schwabe et al., 1992).
The frequency of cholesterol elevations in 32% of our
patients was accordingly higher than would normally be
expected in a rather young population and age-stratified
comparisons with reference groups (Assmann et al., 1986)
showed significantly higher cholesterol levels especially in the
19-29 year-old patients. This finding is of concern as an
increased incidence of arterial hypertension and of myocar-
dial infarctions after ctx for testicular cancer has been
postulated (Berger et al., 1995; Bissett et al., 1990; Gietema
et al., 1992; Roth et al., 1988; Schwabe et al., 1992). Our
results further demonstrate the existence of complex relation-
ships between oestrogens, testicular, adrenal steroids, total
cholesterol and BMI. This is important as DHEA and the
oestrogens El and E2 were directly correlated with type and
dosage of cytotoxic agents, implying that ctx treatment
factors, in addition to patient characteristics such as age and
liver function, may have a significant influence on
cardiovascular risk profiles.
In conclusion, major endocrinological abnormalities
persist in more than half of young patients cured from
testicular cancer by cisplatin-based combination ctx regimens.
Although the complex interaction between hormones and ctx
variables is apparent, it is difficult to establish causal
relationships. None of our patients presented with obvious
clinical symptoms, which was not surprising as an acquired
complete Leydig cell dysfunction would cause physical
changes to appear only very slowly in previously sexually
mature men, or as a major decline of the adrenal androgens
would not produce gross clinical symptoms. Yet, the absence
of apparent clinical toxicity does not exclude the possibiity
of ctx-related secondary morbidity. Subtle shifts in hormonal
ratios might not only represent an important factor for
increased cardiovascular risk, but might additionally affect
other body systems with unknown long-term consequences.
while routine screening continuously presents normal serum
testosterone levels. In order to recognise endocrinological
alterations after ctx, extensive investigation may be necessary.
With the increasing use of high-dose ctx, made possible by
overcoming haematological toxicity through stem cell rescue,
long-term alterations of the hormonal equilibrium may
become even more important. In 1972 Campos postulated
that generalised treatment causes what he called 'continuous
positive ageing' - delaying tumour death through treatment,
but making a 'physiological' death more likely with the
passage of time. Surveillance and adequate supportive
measures should be able to assure that the years of life
gained by therapy are not lost to toxicity.
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